John M. Burke, MD from Rocky Mountain Cancer Centers discusses multiple myeloma study and added daratumumab towards CD38 at the 2017 American Society of Hematology.
John M. Burke, MD from Rocky Mountain Cancer Centers discusses multiple myeloma study and added daratumumab towards CD38 at the 2017 American Society of Hematology.